Stay updated with breaking news from Physical Limitations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
To advance the field, ongoing research and development is imperative. Manufacturers must continue to innovate and customize solutions to overcome adherence challenges.
New long-term follow-up results from two Phase 3 studies evaluating CAMZYOS (mavacamten), a first-in-class cardiac myosin inhibitor, in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) were recently announced by Bristol Myers Squibb.
New long-term follow-up results from two Phase 3 studies evaluating CAMZYOS (mavacamten), a first-in-class cardiac myosin inhibitor, in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) were recently announced by Bristol Myers Squibb.
Results from VALOR-HCM LTE demonstrated that with longer follow-up, CAMZYOS continued to reduce eligibility for invasive SRT at 56 weeks EXPLORER-LTE data showed sustained improvements in LVOT...
Harriette Cole: This is worse than just co-existing with a roommate.